Correlation of enzyme activity and clinical phenotype in POMT1-associated dystroglycanopathies

M. Lommel, PhD
S. Cirak, MD
T. Willer, PhD
R. Hermann, MSc
G. Uyanik, MD
H. van Bokhoven, PhD
C. Körner, PhD
T. Voit, MD
I. Barić, MD
U. Hehr, MD
S. Strahl, PhD

ABSTRACT

Background: Mutations in protein O-mannosyltransferases (POMTs) cause a heterogeneous group of muscular dystrophies with abnormal glycosylation of α-dystroglycan (dystroglycanopathies). The wide spectrum of clinical severities ranges from Walker-Warburg syndrome (WWS), associated with brain and eye abnormalities, to mild forms of limb girdle muscular dystrophy (LGMD).

Objective: The aim of this study was to elucidate the impact of mutations in POMT1 on the clinical phenotype.

Methods: We examined 2 patients with POMT1-associated α-dystroglycanopathy, 1 displaying a LGMD2K and 1 with a WWS phenotype. Using dermal fibroblasts, we analyzed the influence of the POMT1 mutations on the glycosylation status of α-dystroglycan, protein O-mannosyltransferase activity, and the stability of the mutant POMT1 protein.

Results: We report on novel compound heterozygous mutations in POMT1 (p.L171A and p.A589VfsX38) that result in LGMD2K. We further demonstrate that a homozygous splice site mutation of a recently identified WWS patient results in POMT1 p.del77-93. Using dermal fibroblasts, we show that mannosyltransferase activity is reduced in the patients and that stability of POMT1 mutant proteins p.A589VfsX38 and p.del77-93 is significantly decreased.

Conclusions: Our results suggest that dermal fibroblasts can be applied to facilitate the diagnostic analysis of dystroglycanopathy patients as well as to study the pathogenic mechanism of POMT mutations. Characterization of the POMT1 substrate protein α-dystroglycan and POMT in vitro mannosyltransferase activity shows that the severity of the clinical phenotype of the patients analyzed is inversely correlated with POMT activity. Neurology® 2010;74:157–164

GLOSSARY

α-DG = α-dystroglycan; CMD = muscular dystrophies; LGMD = limb girdle muscular dystrophy; MLPA = multiplex ligation-dependent probe amplification; POMT = protein O-mannosyltransferase; WWS = Walker-Warburg syndrome.

In humans, impaired protein O-mannosylation results in congenital muscular dystrophies (CMD) that are referred to as secondary α-dystroglycanopathies since a common pathologic feature is the hypoglycosylation of α-dystroglycan (α-DG).1 The most severe disorder is Walker-Warburg syndrome (WWS, OMIM 236670), characterized by CMD associated with severe brain malformations and ocular abnormalities.2 WWS patients often die within the first year of life. In contrast, the mildest disorders may not present until adulthood, such as limb-girdle muscular dystrophy (LGMD), where neither brain nor eyes are affected.2 In between these extremes, intermediate phenotypes have been described with CMD but mild mental retardation and microcephaly.

From the Heidelberg Institute for Plant Sciences, Dept. V Cell Chemistry, University of Heidelberg, Germany; Institute of Child Health (S.C.), Dubowitz Neuromuscular Centre, University College London, London, UK; Zentrum fuer Kinderheilkunde (R.H., T.V.), Padiatrie 1, Universitaetsklinikum Essen, Germany; Institute for Human Genetics (G.U.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Human Genetics (H.v.B.), Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; Zentrum fuer Kinder- und Jugendmedizin (C.K.), Kinderheilkunde I, Universitaetsklinikum Heidelberg, Germany; Department of Pediatrics (I.B.), University Hospital Center and School of Medicine, Zagreb, Croatia; Center for Human Genetics (U.H.), Regensburg, Germany. T.W. is currently affiliated with Department of Molecular Physiology & Biophysics, The University of Iowa Carver College of Medicine, IA. T.V. is currently affiliated with Institut de Myologie, Université Pierre et Marie Curie Paris 6, UPMC UMR S 974, INSERM U 974, CNRS UMR 7215, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.

Disclosure: Author disclosures are provided at the end of the article.
The protein O-mannosyltransferases POMT1 and POMT2 initiate the biosynthesis of O-mannosyl glycans in the endoplasmic reticulum. Mutations in the POMT1 (OMIM 607423) and POMT2 (OMIM 607439) genes result in α-dystroglycanopathies with overlapping phenotypes. Distinct mutations in POMT1, as well as POMT2, have been identified in patients with WWS, muscle-eye-brain disease (OMIM 253280), and mild forms of CMD such as congenital muscular dystrophy with mental retardation (CMD/MR), LGMD2K based on evidence to support this hypothesis is lacking. However, so far, direct evidence to support this hypothesis is lacking.

In this study, we determine POMT O-mannosyltransferase activity in dermal fibroblasts of patients with different mutations in the POMT1 gene. Our data show an inverse correlation between the degree of the remaining POMT activity and the severity of the clinical phenotype has been postulated. However, so far, direct evidence to support this hypothesis is lacking.

RESULTS Two novel compound heterozygous POMT1 mutations result in LGMD2K phenotype. Patient 1 was originally identified as LGMD2K. The 10-year-old boy was born at term after an uneventful pregnancy. Developmental milestones were delayed with independent walking at 22 months. He developed secondary microcephaly with occipitofrontal circumference of 49 cm (0.7 cm below third centile) at 6 years of age and is mentally retarded with an IQ of 68 (80% interval, 63–79) according to the Snijders-Oomen scale. Brain MRI scans did not reveal structural changes. Serum creatine kinase levels were increased (10× normal) and hypertrophy of the calf muscle and Gowers sign with limb-girdle weakness was observed at 5 years. The muscle biopsy at 3 years of age showed a myopathic pattern and staining with a core antibody against dystrophin revealed a patchy reduction of dystroglycan expression (data not shown).

Patient 2 presented with typical clinical signs of WWS. A 10-year-old male patient was born at term after an uneventful pregnancy. Developmental milestones were delayed with independent walking at 22 months. He developed secondary microcephaly with occipitofrontal circumference of 49 cm (0.7 cm below third centile) at 6 years of age and is mentally retarded with an IQ of 68 (80% interval, 63–79) according to the Snijders-Oomen scale. Brain MRI scans did not reveal structural changes. Serum creatine kinase levels were increased (10× normal) and hypertrophy of the calf muscle and Gowers sign with limb-girdle weakness was observed at 5 years. The muscle biopsy at 3 years of age showed a myopathic pattern and staining with a core antibody against dystrophin revealed a patchy reduction of dystroglycan expression (data not shown).

RESULTS Two novel compound heterozygous POMT1 mutations result in LGMD2K phenotype. Patient 1 was originally identified as LGMD with mental retardation (for details, see Methods). Sequencing of all coding exons of POMT1 revealed a novel heterozygous missense mutation in exon 6 (data not shown) predicting a substitution of the conserved leucine residue Leu171 to alanine (p.L171A; NCBI reference sequence: NP_009102.3) in the POMT1 protein (figure 1A). This substitution was not observed in 51 healthy control subjects of European descent, and is not present in SNP databases or human EST clones. Sequencing of the coding exons of POMT2 and FKRP did not reveal any mutations. Thus, we performed MLPA-analysis for POMT1 which identified a partial heterozygous deletion at the exon 19 probe (data not shown). For further refinement, we performed RT-PCR analyses of POMT1 transcripts. Total RNA from patient 1 and a healthy control was reverse transcribed with oligo-dT primers. POMT1 cDNA was amplified by nested PCR. Primer sequences are listed in table e-1 on the Neurology® Web site at www.neurology.org. PCR products were separated on 1.5% agarose gels or cloned into a TOPO-TA Cloning Vector (Invitrogen) for sequencing.

Antibody production. Anti-POMT1 antiserum was produced using a synthetic peptide corresponding to aa Arg-249 to His-364 of mouse POMT1. The peptide was coupled to keyhole limpet hemocyanin and injected into rabbits. Antibodies were purified using the peptide bound to cyanogen bromide-activated Sepharose. Peptide synthesis, coupling, immunizations, and affinity purifications were done at Pineda Antikörper Service (Berlin/Germany).

Isolation of microsomal membrane fractions. Microsomal membrane fractions from cultured cells were isolated as described previously. Microsomal membranes were resuspended in 20 mM Tris-HCl pH 8.0, 10 mM EDTA. Protein concentration was determined using the D2-Protein Assay (BioRad).

Wheat germ agglutinin–glycoprotein enrichment. Cultured fibroblasts were washed with PBS containing protease inhibitors and harvested in the same buffer. Cell pellets were processed as described elsewhere.

Western blot analyses. Microsomal membranes (180 µg protein) or wheat germ agglutinin–enriched glycoprotein fractions were separated on 8% SDS–polyacrylamide gels and transferred to nitrocellulose. Polyclonal anti-POMT1, monoclonal anti-α-dystroglycan (HH6, Upstate), and polyclonal anti-β-dystroglycan (C20, Santa Cruz Biotechnologies Inc.) antibodies were used. After decoration with peroxidase-coupled secondary antibodies immunoreactivity was visualized by chemiluminescence.

ASSAY for protein O-mannosyltransferase activity. Protein O-mannosyltransferase activity was determined based on the amount of [3H]-mannose transferred from Dol-P-[3H]-mannose to POMT1.

RESULTS Two novel compound heterozygous POMT1 mutations result in LGMD2K phenotype. Patient 1 was originally identified as LGMD with mental retardation (for details, see Methods). Sequencing of all coding exons of POMT1 revealed a novel heterozygous missense mutation in exon 6 (data not shown) predicting a substitution of the conserved leucine residue Leu171 to alanine (p.L171A; NCBI reference sequence: NP_009102.3) in the POMT1 protein (figure 1A). This substitution was not observed in 51 healthy control subjects of European descent, and is not present in SNP databases or human EST clones. Sequencing of the coding exons of POMT2 and FKRP did not reveal any mutations. Thus, we performed MLPA-analysis for POMT1 which identified a partial heterozygous deletion at the exon 19 probe (data not shown). For further refinement, we performed RT-PCR analyses of POMT1 transcripts. Total RNA from patient 1 and a healthy control was reverse transcribed with oligo-dT primers. POMT1 cDNA was amplified by nested PCR. Primer sequences are listed in table e-1 on the Neurology® Web site at www.neurology.org. PCR products were separated on 1.5% agarose gels or cloned into a TOPO-TA Cloning Vector (Invitrogen) for sequencing.
primers. PCR reactions using primer combinations that cover the POMT1 cDNA coding exons resulted in products of the expected size (figure 1, B and D). However, amplification of the cDNA spanning exon 18 and exon 19 (primers 1843F/2583R, figure 1B) besides the expected 740 bp product resulted in an additional PCR fragment of approximately 440 bp only in the patient (figure 1D). The observed 300-bp difference between these PCR products suggested a heterozygous deletion of exon 18 to exon 19 in the patient. Sequencing of the PCR products verified this deletion (figure 1C). The lack of exon 18 to exon 19 in the POMT1 transcript results in a frameshift mutation, causing an amino acid change at position 589 from alanine to valine, followed by a premature stop codon after 38 amino acids (p.A589VfsX38).

A homozygous splice site mutation causes deletion of exon 4 in POMT1-WWS patient. Patient 2 was recently identified as WWS carrying a homozygous base substitution at the 5’-splice donor site of intron 4 (c.280 + 1G>T; NM_007171). This mutation is likely to impair the correct splicing of the POMT1 precursor mRNA. To further analyze the hypothesized splicing defect, we characterized the POMT1 cDNA amplified from dermal fibroblasts of patient 2 and 2 control cell lines. PCR analysis using a primer combination flanking exon 4 (tw297/tw298; figure 2A) resulted in the expected 252 bp fragments in the control cDNA, whereas in the WWS patient the detected fragment is approximately 50 bp smaller (figure 2B, upper panel). The observed difference in the length of the PCR products suggested a deletion of exon 4 (51 bp) in the patient’s mRNA. Deletion of exon 4 is further supported by the fact that a RT-PCR reaction using 1 primer within exon 4 (tw296 and tw298; figure 2A) resulted in the expected 197 bp POMT1 PCR fragment in the control cDNA, but was absent in the patient (figure 2B, lower panel). Sequence analysis of the 201 bp PCR fragment (tw297 and tw298; figure 2, A and B) verified the
deletion of exon 4 (figure 2C). Taken together, the mutation of the 5′-splice donor site of intron 4 causes skipping of exon 4 during processing of the POMT1 precursor mRNA. Deletion of exon 4 results in the loss of 17 amino acids (p.del77-93) within the putative catalytic domain between the first and the second transmembrane domain of the POMT1 protein.

Glycosylation of α-DG and POMT O-mannosyltransferase activity correlate with the phenotype of the secondary dystroglycanopathies. Both the LGMD2K and the WWS patient carry POMT1 mutations; however, they both resemble opposite ends of the clinical spectrum within the secondary α-dystroglycanopathies. To characterize in more detail how the respective POMT1 mutations contribute to the clinical picture, we analyzed the O-mannosylation status of the POMT1 substrate α-DG. Wheat germ agglutinin glycoprotein-enriched fractions prepared from dermal fibroblast cell lines were analyzed by Western blot. Antibodies directed toward a so far unidentified O-mannosyl-linked glyco-epitope on α-DG (IIH6) detected α-DG variants between 100 and 125 kDa in control cells (figure 3; lane 1). Similar variants were detected in extracts derived from the LGMD2K patient but to a highly reduced amount (figure 3; lane 2). In contrast, no IIH6 positive α-DG was detectable in the WWS patient (figure 3; lane 3). Equal loading was confirmed by detection of β-dystroglycan. These findings confirm a direct correlation between the severity of the clinical phenotype and the degree of functionally O-mannosylated α-DG.

We further analyzed whether differences in the O-mannosylation state of α-DG are reflecting differences in POMT activity in patient cells. To this end, we measured in vitro POMT mannosyltransferase activity in dermal fibroblasts of the patients. First, we adapted an enzymatic assay that was previously described for human embryonic kidney fibroblast (HEK 293) cells and lymphoblasts.15,17 POMT activity in human dermal fibroblasts highly exceeds the activity in HEK 293 cells (data not shown).15 A linear increase in the transfer of radioactive mannose to the mannosyl acceptor was observed within the range of 20 μg to 120 μg of microsomal membranes (fig-
To ensure that the mannose donor is not limiting to the reaction, increasing amounts of Dol-P-Man were added. As shown in figure 4A, excess of the mannosyl donor was achieved between 1 pmol and 2 pmol. According to these results, enzyme activity was determined using 2 pmol of Dol-P-[3H]Man and 80 μg of microsomal membranes derived from controls and patients. Although POMT activities among the tested control cell lines showed some variability, a clear reduction was observed in the analyzed patients. When compared to the controls, ~40% residual activity was detected in the LGMD2K patient (figure 4B). In contrast, in the WWS patient described above (POMT1 p.del77-93) only 6% residual POMT activity was detected. An additional WWS patient14 (POMT1 mutation: G76R; NP_009102.3) showed ~10% residual POMT activity.

Our data show that the degree of α-DG O-mannosylation and the enzymatic activity of the mutated POMT1 protein inversely correlate with the phenotypic severity observed in the patients analyzed.

Amino acid deletions affect stability of mutant POMT1 proteins. Since POMT1 mutations differently affect enzymatic activity, we further analyzed their impact on the POMT1 protein. We performed Western blot analysis of microsomal membranes from control and patient-derived dermal fibroblast cells. For POMT1 detection, we generated antibodies directed against a 15 amino acid peptide (Arg-249 to His-364) located in the central hydrophilic domain of mouse POMT1 (described in Methods). This domain is not affected in the analyzed POMT1 patients. As shown in figure 5 (lane 1), on Western blot wild-type POMT1 can be detected with an apparent molecular weight of 85 kDa. In accordance with the two POMT1 mutant alleles, 2 proteins are observed in the LGMD2K patient. The 85 kDa protein corresponds to the POMT1 p.L171A amino acid substitution, whereas the 71 kDa protein represents the p.A589VfsX38 mutant form of POMT1 (figure 5; lane 2). Comparing the quantities of the 2 proteins, the amount of p.A589VfsX38 POMT1 appears to be significantly lower, suggesting decreased stability of the mutant protein. Remarkably, in the WWS patient POMT1 p.del77-93 could not be detected (figure 5; lane 3), although the mutant protein lacking amino acids 77–93 does contain the anti-POMT1 epitope. Our data show that deletion of different regions of POMT1 affects protein stability. In contrast, amino acid substitution p.L171A results in a stable but less active POMT1 protein coinciding with the milder phenotype of the LGMD2K patient.

DISCUSSION

We identified 2 novel POMT1 mutations that in combination result in LGMD2K phenotype (figure 1). Mutation p.A589VfsX38 causes deletion of the C-terminal 158 amino acids including 2 putative transmembrane spans and the loop6 domain (figure e-1). This deletion significantly affected POMT1 protein stability (figure 5). In contrast, amino acid substitution p.L171A resulted in decreased O-mannosyltransferase activity without affecting POMT1 stability (figures 4 and 5). Leu171 is conserved in vertebrate and invertebrate POMT1s (figure 1A) which provides further pathologic evidence. In addition, we characterized a POMT1 mutation p.del77-93 that results in WWS14 (figure 2). This mutation has also been reported in 2 other WWS patients.18 The POMT1 p.del77-93 protein lacks 17 amino acids within a hydrophilic domain between 2 putative transmembrane spans close to the N-terminus of the protein (figure e-1). This region has been demonstrated to be essential for protein O-mannosyltransferase activity in yeast.19 Western blot analyses suggest that the mutation affects protein stability and that the POMT1 p.del77-93 mutant protein is degraded in the patient (figure 5).

We determined POMT1 activity in dermal fibroblast cells of these patients. In agreement with the lack of the POMT1 protein, the WWS patient (figures 3 and 4) is characterized by abolished in vitro as...
as well as in vivo O-mannosylation of α-DG. In mammals, POMT1-POMT2 complexes are formed and complex formation is a prerequisite for full enzymatic activity.\textsuperscript{15,20} However, POMT2 might be enzymatically active in the absence of POMT1 and therefore account for the low residual in vitro activity detected (6% residual activity) in the WWS samples.\textsuperscript{21} Studies with protein O-mannosyltransferases (PMTs) of yeast substantiate this assumption. In yeast, Pmt1p and Pmt2p form heteromeric complexes; however, the individual Pmt-proteins show low levels of in vitro activity, even in the absence of their complex partner.\textsuperscript{22,23} Compared to the WWS patient, in vitro as well as in vivo O-mannosylation of α-DG is less affected in the LGMD2K patient (figures 3 and 4).

Using dermal fibroblasts as enzyme source to measure POMT activity, we provide direct evidence that POMT activity correlates with the severity of symptoms of the analyzed dystroglycanopathy patients (figure 4). Future studies with larger patient cohorts will be necessary to corroborate our hypothesis of inverse correlation between residual enzymatic POMT activity in POMT1 patients and the clinical phenotype. Recently it was shown that POMT activities are abolished in lymphoblasts from various patients with POMT1 or POMT2 mutations.\textsuperscript{17} Even more, lymphoblastoid cell lines from a LGMD2K patient carrying a homozygous POMT1 pA200P mutation\textsuperscript{5} showed almost no POMT activity as it was observed in WWS cases.\textsuperscript{17} The reported POMT activity in lymphoblastoid cells of those patients (non detectable to \~0.004 pmol/hour/mg protein\textsuperscript{17}) was at least 10 times lower compared to activities in patients’ dermal fibroblasts analyzed in this study (figure 4). Thus, it is probably difficult to resolve differences in POMT activity in patient lymphoblasts. Comparative histologic analyses of muscle cross sections stained with antibodies directed toward an O-mannosidically linked glycoepitope of α-DG showed that staining intensities correlated with the severity of the clinical phenotype of the patients.\textsuperscript{24,25} Thus, so far only indirect evidence suggested a correlation between the clinical phenotype

(A) Correlation of POMT enzyme activity with the amount of microsomal membranes and Dol-P-[\textsuperscript{3H}]Man were recorded to determine the linear range for the POMT enzyme assay. (B) POMT activities in control cells and patient-derived dermal fibroblasts. POMT activity was based on the rate of radioactive [\textsuperscript{3H}]mannose transfer from Dol-P-[\textsuperscript{3H}]Man (125,000 dpm/pmol) to a GST-α-DG fusion protein.

Figure 4 POMT enzyme activity in POMT1 associated α-dystroglycanopathies

(A) Transfer (dpm) vs. µg Membranes
(B) Transfer (dpm) vs. Dol-P-Man (pmol)
and POMT activity in POMT1 and POMT2 associated α-dystroglycanopathy patients.

Our study shows that dermal fibroblasts provide a source to detect defects caused by mutations in POMTs. This is especially important with respect to diagnosis of CMD patients. Besides POMT1 and POMT2, 4 additional genes—POMGnTI (OMIM 606822), Fukutin-related protein (OMIM 606596), Fukutin (OMIM 607440), and LARGE (OMIM 603590)—have been established to cause secondary α-dystroglycanopathies in humans.2 Since there is a strong overlap in the clinical features between mutations in these genes, sequencing of up to 6 genes is necessary to identify the causative mutation. Furthermore, recent studies9,17,26 demonstrated intragenic deletions and splicing abnormalities due to deep intronic mutations of POMT1 and POMT2, which have been missed by genomic sequencing of exons and flanking intronic sequences. Therefore, testing of POMT enzymatic activity provides a valuable diagnostic tool for this group of patients. Here we show that POMT activity can be measured in control and patient primary dermal fibroblasts (figure 4B). This assay represents an accurate functional method to prescreen patients harboring POMT1 and POMT2 mutations among those with suspected or confirmed α-dystroglycanopathies. Besides the measurement of POMT activity, the use of fibroblasts will also allow the evaluation of α-DG which is expressed in these cells (figure 3).27 Therefore, the use of dermal fibroblast cells may circumvent the need for invasive muscle biopsies when clinical findings are suggestive of secondary α-dystroglycanopathies and exonic sequencing has not revealed pathogenic mutations.

ACKNOWLEDGMENT

The authors thank C. Endres for technical assistance. S. Strahl is a member of CellNetworks—Cluster of Excellence (EXC81).

DISCLOSURE

Dr. Lommel reports no disclosures. Dr. Cirak has received research support from the German Federal Ministry of Education and Research. Dr. Willer reports no disclosures. R. Herrmann has received research support from the German Federal Ministry of Education and Research. Dr. Uyanik reports no disclosures. Dr. van Bokhoven has received research support from Primes Beatrix Foundation (Netherlands). Dr. Köner reports no disclosures. Dr. Voit has served on scientific advisory boards for Santiveri Pharmaceuticals, Amicus Therapeutics, Inc., and AVI BioPharma; serves as Executive Editor of Neuropediatrics and an Associate Editor of Neuromuscular Disorders; may accrue revenue on patent 21512/0210136-US0, filed 2009; Tricisly DNA antisense oligonucleotides, compositions, and methods for the treatment of disease; and has received research support from the Ministry of Science, Education and Sports of Republic of Croatia. Dr. Hehr reports no disclosures. Dr. Strahl has received research support from the Deutsche Forschungsgemeinschaft (grant STR443/2).

REFERENCES


Received July 22, 2009. Accepted in final form October 29, 2009.

Editor’s Note to Authors and Readers: Levels of Evidence in Neurology®

Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to Neurology® that report on clinical therapeutic studies must state the study type, the primary research question(s), and the classification of level of evidence assigned to each question based on the AAN classification scheme requirements. While the authors will initially assign a level of evidence, the final level will be adjudicated by an independent team prior to publication. Ultimately, these levels can be translated into classes of recommendations for clinical care. For more information, please access the articles and the editorial on the use of classification of levels of evidence published in Neurology.1-3